VTGN Stock Summary and Trading Ideas (Vistagen Therapeutics | NASDAQ:VTGN)

Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.

Vistagen Therapeutics trades on the NASDAQ stock market under the symbol VTGN.

As of May 1, 2026, VTGN stock price climbed to $0.63 with 427,015 million shares trading.

VTGN has a beta of 1.18, meaning it tends to be more sensitive to market movements. VTGN has a correlation of 0.01 to the broad based SPY ETF.

VTGN has a market cap of $24.79 million. This is considered a Sub-Micro Cap stock.

Last quarter Vistagen Therapeutics reported $303,000 in Revenue and -$.45 earnings per share. This beat revenue expectation by $46,480 and missed earnings estimates by -$.06.

In the last 3 years, VTGN traded as high as $24.71 and as low as $.43.

The top ETF exchange traded funds that VTGN belongs to (by Net Assets): VTI, VXF, PSIL, IWC.

VTGN has underperformed the market in the last year with a price return of -73.5% while the SPY ETF gained +30.4%. However, in the short term, VTGN had mixed performance relative to the market. It has outperformed in the last 3 months, returning +12.1% vs +4.4% return in SPY. But in the last 2 weeks, VTGN shares have been beat by the market, returning -0.3% compared to an SPY return of +1.5%.

VTGN support price is $.58 and resistance is $.64 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VTGN shares will trade within this expected range on the day.